company background image
NOVN.Q logo

NVN Liquidation OTCPK:NOVN.Q Stock Report

Last Price

US$0.000001

Market Cap

US$28.0

7D

-99.9%

1Y

-100.0%

Updated

01 May, 2024

Data

Company Financials

NVN Liquidation, Inc.

OTCPK:NOVN.Q Stock Report

Market Cap: US$28.0

NOVN.Q Stock Overview

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. More details

NOVN.Q fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

NVN Liquidation, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for NVN Liquidation
Historical stock prices
Current Share PriceUS$0.000001
52 Week HighUS$1.38
52 Week LowUS$0.000001
Beta1.65
1 Month Change-99.88%
3 Month Change-99.00%
1 Year Change-100.00%
3 Year Change-100.00%
5 Year Change-100.00%
Change since IPO-100.00%

Recent News & Updates

Recent updates

Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Jun 07
Take Care Before Diving Into The Deep End On Novan, Inc. (NASDAQ:NOVN)

Novan Q2 2022 Earnings Preview

Aug 10

Novan pays off $16.5M in outstanding promissory note related to EPI Health acquisition

Jul 19

Novan shares under pressure after proposing capital raise

Jun 16

Novan’s NVN4100 shows antimicrobial effect against bacteria in animal health

Jun 07

Novan: Q2 2021's SB206 Readout Is Life Or Death For This NO-Based Biotech

Apr 28

Novan regains Nasdaq compliance for minimum bid price requirement

Jan 29

Novan EPS in-line, beats on revenue

Oct 30

Shareholder Returns

NOVN.QUS PharmaceuticalsUS Market
7D-99.9%-1.5%-2.4%
1Y-100.0%7.9%23.4%

Return vs Industry: NOVN.Q underperformed the US Pharmaceuticals industry which returned 11.6% over the past year.

Return vs Market: NOVN.Q underperformed the US Market which returned 22.3% over the past year.

Price Volatility

Is NOVN.Q's price volatile compared to industry and market?
NOVN.Q volatility
NOVN.Q Average Weekly Movement1,535.8%
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: NOVN.Q's share price has been volatile over the past 3 months.

Volatility Over Time: NOVN.Q's weekly volatility has decreased from 1617% to 1536% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200690Scott Pleshawww.novan.com

NVN Liquidation, Inc., a medical dermatology company, focuses on developing and commercializing therapeutic products for skin diseases. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete’s foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2.

NVN Liquidation, Inc. Fundamentals Summary

How do NVN Liquidation's earnings and revenue compare to its market cap?
NOVN.Q fundamental statistics
Market capUS$28.00
Earnings (TTM)-US$32.05m
Revenue (TTM)US$24.92m

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NOVN.Q income statement (TTM)
RevenueUS$24.92m
Cost of RevenueUS$24.45m
Gross ProfitUS$473.00k
Other ExpensesUS$32.52m
Earnings-US$32.05m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.14
Gross Margin1.90%
Net Profit Margin-128.61%
Debt/Equity Ratio-1,164.1%

How did NOVN.Q perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/05/01 09:25
End of Day Share Price 2024/05/01 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

NVN Liquidation, Inc. is covered by 8 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian Kemp DolliverBrookline Capital Markets
Jennifer KimCantor Fitzgerald & Co.
Oren LivnatH.C. Wainwright & Co.